NeuroPace (NPCE) – Analysts’ Weekly Ratings Updates

NeuroPace (NASDAQ: NPCE) has recently received a number of price target changes and ratings updates:

• 11/5/2025 – NeuroPace had its “outperform” rating reaffirmed by analysts at Leerink Partners. They now have a $19.00 price target on the stock.
• 11/5/2025 – NeuroPace had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $16.00 price target on the stock.
• 11/5/2025 – NeuroPace had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $18.00. They now have an “overweight” rating on the stock.
• 11/5/2025 – NeuroPace had its price target raised by analysts at Wells Fargo & Company from $15.00 to $16.00. They now have an “overweight” rating on the stock.
• 10/8/2025 – NeuroPace had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – NeuroPace had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.